GlassScriptPhysician profile
Lilia Nikolayev
NPI 1952493132
$8,294.31
in general payments reported to CMS, 2019-2025
20 companies · $1,706 in 2025
The $1,706 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $296 · 2021: $1,142 · 2022: $1,400 · 2023: $1,803 · 2024: $1,370 · 2025: $1,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,879.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,182.28 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,142.94 | 2020-2025 | Caplyta |
| Alkermes, INC. | $841.54 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $818.00 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $540.62 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $518.90 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $418.71 | 2020-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $407.27 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $321.54 | 2019-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Vanda Pharmaceuticals INC. | $318.85 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $274.00 | 2021-2025 | Trintellix |
| Lundbeck LLC | $164.18 | 2021-2025 | Rexulti |
| Corium, LLC | $150.11 | 2022-2024 | Azstarys |
| Noven Therapeutics, LLC | $57.45 | 2021-2025 | Xelstrym |
| Allergan, INC. | $47.20 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $24.87 | 2025 | Cobenfy |
| Almatica Pharma LLC | $23.90 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.09 | 2022 | |
| Eisai INC. | $13.34 | 2021 | |
| Bausch Health US, LLC | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilia Nikolayev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.